Dr Murugan Kalimutho

Hancock, Janelle L., Kalimutho, Murugan, Straube, Jasmin, Lim, Malcolm, Gresshoff, Irma, Saunus, Jodi M., Lee, Jason S., Lakhani, Sunil R., Simpson, Kaylene J., Bush, Ashley I., Anderson, Robin L. and Khanna, Kum Kum (2023). COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. Journal of Experimental and Clinical Cancer Research, 42 (1) 90, 1-16. doi: 10.1186/s13046-023-02663-8

Raninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) ARTN 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011

Lu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V. and Khanna, Kum Kum (2022). CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors. Journal of Experimental and Clinical Cancer Research, 41 (1) 355, 1-17. doi: 10.1186/s13046-022-02570-4

Maniam, Pramila, Essilfie, Ama-Tawiah, Kalimutho, Murugan, Ling, Dora, Frazer, David M., Phipps, Simon, Anderson, Gregory J. and Reid, David W. (2021). Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosis. Biological Research, 54 (1) 38. doi: 10.1186/s40659-021-00361-3

Rashidieh, Behnam, Shohayeb, Belal, Bain, Amanda Louise, Fortuna, Patrick R. J., Sinha, Debottam, Burgess, Andrew, Mills, Richard, Adams, Rachael C., Lopez, J. Alejandro, Blumbergs, Peter, Finnie, John, Kalimutho, Murugan, Piper, Michael, Hudson, James Edward, Ng, Dominic C. H. and Khanna, Kum Kum (2021). Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis. PLoS Genetics, 17 (10) e1009334, 1-31. doi: 10.1371/journal.pgen.1009334

Rashidieh, Behnam, Molakarimi, Maryam, Mohseni, Ammar, Tria, Simon Manuel, Truong, Hein, Srihari, Sriganesh, Adams, Rachael C., Jones, Mathew, Duijf, Pascal H. G., Kalimutho, Murugan and Khanna, Kum Kum (2021). Targeting BRF2 in cancer using repurposed drugs. Cancers, 13 (15) 3778, 1-28. doi: 10.3390/cancers13153778

Makhale, Ashwini, Nanayakkara, Devathri, Raninga, Prahlad, Khanna, Kum Kum and Kalimutho, Murugan (2021). CX-5461 enhances the efficacy of APR-246 via induction of DNA damage and replication stress in triple-negative breast cancer. International Journal of Molecular Sciences, 22 (11) ARTN 5782, 5782. doi: 10.3390/ijms22115782

Sinha, Debottam, Nag, Purba, Nanayakkara, Devathri, Duijf, Pascal H. G., Burgess, Andrew, Raninga, Prahlad, Smits, Veronique A. J., Bain, Amanda L., Subramanian, Goutham, Wall, Meaghan, Finnie, John. W., Kalimutho, Murugan and Khanna, Kum Kum (2020). Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Communications Biology, 3 (1) 593, 1-16. doi: 10.1038/s42003-020-01304-6

Raninga, Prahlad V., Lee, Andy C., Sinha, Debottam, Shih, Yu-Yin, Mittal, Deepak, Makhale, Ashwini, Bain, Amanda L., Nanayakarra, Devathri, Tonissen, Kathryn F., Kalimutho, Murugan and Khanna, Kum Kum (2020). Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. International Journal of Cancer, 146 (1), 123-136. doi: 10.1002/ijc.32410

Raninga, Prahlad, Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava, Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle M., Pouliot, Normand M., Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri and Khanna, Kum Kum (2020). Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics, 10 (12), 5259-5275. doi: 10.7150/thno.42705

Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2019). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer (vol 8, 73, 2018). Scientific Reports, 9 ARTN 18771. doi: 10.1038/s41598-019-55020-1

Duijf, Pascal H.G., Nanayakkara, Devathri, Nones, K., Srihari, Sriganesh, Kalimutho, Murugan and Khanna, Kum Kum (2019). Mechanisms of genomic instability in breast cancer. Trends in Molecular Medicine, 25 (7), 595-611. doi: 10.1016/j.molmed.2019.04.004

Yang, Ren-Ming, Nanayakkara, Devathri, Kalimutho, Murugan, Mitra, Partha, Khanna, Kum Kum, Dray, Eloise and Gonda, Thomas J. (2019). MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells. Oncogene, 38 (26), 5239-5249. doi: 10.1038/s41388-019-0789-3

Kalimutho, Murugan, Nones, Katia, Srihari, Sriganesh, Duijf, Pascal H.G., Waddell, Nicola and Khanna, Kum Kum (2019). Patterns of genomic instability in breast cancer. Trends in Pharmacological Sciences, 40 (3), 198-211. doi: 10.1016/j.tips.2019.01.005

Kalimutho, Murugan, Sinha, Debottam, Mittal, Deepak, Srihari, Sriganesh, Nanayakkara, Devathri, Shafique, Shagufta, Raninga, Prahlad, Nag, Purba, Parsons, Kate and Khanna, Kum Kum (2019). Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 38 (1) 85, 1-18. doi: 10.1186/s13046-019-1075-5

Kalimutho, Murugan, Sinha, Debottam, Jeffery, Jessie, Nones, Katia, Srihari, Sriganesh, Fernando, Winnie C., Duijf, Pascal H. G., Vennin, Claire, Raninga, Prahlad, Nanayakkara, Devathri, Mittal, Deepak, Saunus, Jodi M., Lakhani, Sunil R., López, J Alejandro, Spring, Kevin J., Timpson, Paul, Gabrielli, Brian, Waddell, Nicola and Khanna, Kum Kum (2018). CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Molecular Medicine, 10 (9) e8566. doi: 10.15252/emmm.201708566

Sinha, Debottam, Kalimutho, Murugan, Bowles, Josephine, Chan, Ai-Leen, Merriner, D. Jo, Bain, Amanda L., Simmons, Jacinta L., Freire, Raimundo, Lopez, J Alejandro, Hobbs, Robin M., O'Bryan, Moira K. and Khanna, Kum Kum (2018). Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling. The FASEB Journal, 32 (9), 4984-4999. doi: 10.1096/fj.201701096RR

Maniam, P., Kalimutho, M., Embi, N. and Sidek, H. M. (2018). GSK3β inhibition confers survival advantage in Burkholderia pseudomallei-infected hyperglycaemic mice by regulating inflammatory response. Tropical Biomedicine, 35 (1), 228-238.

Boulding, T., McCuaig, R. D., Tan, A., Hardy, K., Wu, F., Dunn, J., Kalimutho, M., Sutton, C. R., Forwood, J. K., Bert, A. G., Goodall, G. J., Malik, L., Yip, D., Dahlstrom, J. E., Zafar, A., Khanna, K. K. and Rao, S. (2018). LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer. Scientific Reports, 8 (1) ARTN 73. doi: 10.1038/s41598-017-17913-x

Kalimutho, Murugan, Bain, Amanda L., Mukherjee, Bipasha, Nag, Purba, Nanayakkara, Devathri M., Harten, Sarah K., Harris, Janelle L., Subramanian, Goutham N., Sinha, Debottam, Shirasawa, Senji, Srihari, Sriganesh, Burma, Sandeep and Khanna, Kum Kum (2017). Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Molecular Oncology, 11 (5), 470-490. doi: 10.1002/1878-0261.12040

Jeffery, J. M., Kalimutho, M., Johansson, P., Cardenas, D. G., Kumar, R. and Khanna, K. K. (2017). FBXO31 protects against genomic instability by capping FOXM1 levels at the G2/M transition. Oncogene, 36 (7), 1012-1022. doi: 10.1038/onc.2016.268

Anderson, Alison M., Kalimutho, Murugan, Harten, Sarah, Nanayakkara, Devathri M., Khanna, Kum Kum and Ragan, Mark A. (2017). The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells. Scientific Reports, 7 (1) 39873. doi: 10.1038/srep39873

Bond, Catherine E., McKeone, Diane M., Kalimutho, Murugan, Bettington, Mark L., Pearson, Sally-Ann, Dumenil, Troy D., Wockner, Leesa F., Burge, Matthew, Leggett, Barbara A. and Whitehall, Vicki L. J. (2016). RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget, 7 (43), 70589-70600. doi: 10.18632/oncotarget.12130

Mittal, Deepak, Sinha, Debottam, Barkauskas, Deborah, Young, Arabella, Kalimutho, Murugan, Stannard, Kimberley, Caramia, Franco, Haibe-Kains, Benjamin, Stagg, John, Khanna, Kum Kum, Loi, Sherene and Smyth, Mark J. (2016). Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Research, 76 (15), 4372-4382. doi: 10.1158/0008-5472.CAN-16-0544

Srihari, Sriganesh, Kalimutho, Murugan, Lal, Samir, Singla, Jitin, Patel, Dhaval, Simpson, Peter T., Khanna, Kum Kum and Ragan, Mark A. (2016). Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. Molecular Biosystems, 12 (3), 963-972. doi: 10.1039/C5MB00655D

Kalimutho, Murugan, Parsons, Kate, Mittal, Deepak, Lopez, J.Alejandro, Srihari, Sriganesh and Khanna, Kum Kum (2015). Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 36 (12), 822-846. doi: 10.1016/j.tips.2015.08.009

Jeffery, J., Sinha, D., Srihari, S., Kalimutho, M. and Khanna, K. K. (2015). Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. Oncogene, 35 (6), 683-690. doi: 10.1038/onc.2015.128

de Andrade, Lucas Ferrari, Ngiow, Shin F., Stannard, Kimberly, Rusakiewicz, Sylvie, Kalimutho, Murugan, Khanna, Kum Kum, Tey, Siok-Keen, Takeda, Kazyuoshi, Zitvogel, Laurence, Martinet, Ludovic and Smyth, Mark J. (2014). Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Research, 74 (24), 7298-7308. doi: 10.1158/0008-5472.CAN-14-1339

Van Schaeybroeck, Sandra, Kalimutho, Murugan, Dunne, Philip D., Carson, Robbie, Allen, Wendy, Jithesh, Puthen V., Redmond, Keara L., Sasazuki, Takehiko, Shirasawa, Senji, Blayney, Jaine, Michieli, Paolo, Fenning, Cathy, Lenz, Heinz-Josef, Lawler, Mark, Longley, Daniel B. and Johnston, Patrick G. (2014). ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer. Cell Reports, 7 (6), 1940-1955. doi: 10.1016/j.celrep.2014.05.032

Al-Ejeh, Fares, Pajic, Marina, Shi, Wei, Kalimutho, Murugan, Miranda, Mariska, Nagrial, Adnan M., Chou, Angela, Biankin, Andrew V., Grimmond, Sean M., Brown, Michael P. and Khanna, Kum Kum (2014). Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Clinical Cancer Research, 20 (12), 3187-3197. doi: 10.1158/1078-0432.CCR-14-0048

Al-Ejeh, F., Simpson, P. T., Sanus, J. M., Klein, K., Kalimutho, M., Shi, W., Miranda, M., Kutasovic, J., Raghavendra, A., Madore, J., Reid, L., Krause, L., Chenevix-Trench, G., Lakhani, S. R. and Khanna, K. K. (2014). Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis, 3 (4) e100, 1-12. doi: 10.1038/oncsis.2014.14

Dunne, Philip D., McArt, Darragh G., Blayney, Jaine K., Kalimutho, Murugan, Greer, Samanda, Wang, Tingting, Srivastava, Supriya, Ong, Chee Wee, Arthur, Ken, Loughrey, Maurice, Redmond, Keara, Longley, Daniel B., Salto-Tellez, Manuel, Johnston, Patrick G. and Van Schaeybroeck, Sandra (2014). AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. Clinical Cancer Research, 20 (1), 164-175. doi: 10.1158/1078-0432.CCR-13-1354

Kalimutho, Murugan, Blanco, Giovanna Del Vecchio, Di Cecilia, Serena, Sileri, Pierpaolo, Cretella, Micaela, Pallone, Francesco, Federici, Giorgio and Bernardini, Sergio (2011). Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. Journal of Gastroenterology, 46 (12), 1391-1402. doi: 10.1007/s00535-011-0456-0

Kalimutho, Murugan, Minutolo, Antonella, Grelli, Sandro, Federici, Giorgio and Bernardini, Sergio (2011). Platinum-(IV)-derivative satraplatin induced G₂/M cell cycle perturbation via p53-p21^waf1/cip1-independent pathway in human colorectal cancer cells. Acta Pharmacologica Sinica, 32 (11), 1387-1396. doi: 10.1038/aps.2011.107

Formosa, Amanda, Piro, Maria Cristina, Docimo, Raffaella, Maturo, Paolo, Sollecito, Daniela Rita Maria, Kalimutho, Murugan, Sancesario, Giulia, Barlattani, Alberto, Melino, Gerry, Candi, Eleonora and Bernardini, Sergio (2011). Salivary miRNAome profiling uncovers epithelial and proliferative miRNAs with differential expression across dentition stages. Cell Cycle, 10 (19), 3359-3368. doi: 10.4161/cc.10.19.17647

Kalimutho, Murugan, Minutolo, Antonella, Grelli, Sandro, Formosa, Amanda, Sancesario, Giulia, Valentini, Alessandra, Federici, Giorgio and Bernardini, Sergio (2011). Satraplatin (JM-216) mediates G2/M cell cycle arrest and potentiates apoptosis via multiple death pathways in colorectal cancer cells thus overcoming platinum chemo-resistance. Cancer Chemotherapy and Pharmacology, 67 (6), 1299-1312. doi: 10.1007/s00280-010-1428-4

Kalimutho, M., Di Cecilia, S., Blanco, G. Del Vecchio, Roviello, F., Sileri, P., Cretella, M., Formosa, A., Corso, G., Marrelli, D., Pallone, F., Federici, G. and Bernardini, S. (2011). Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. British Journal of Cancer, 104 (11), 1770-1778. doi: 10.1038/bjc.2011.82

Kalimutho, Murugan, Blanco, Giovanna Del Vecchio, Cretella, Micaela, Mannisi, Elena, Sileri, Pierpaolo, Formosa, Amanda, Pallone, Francesco, Federici, Giorgio and Bernardini, Sergio (2011). A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection. International Journal of Colorectal Disease, 26 (5), 583-592. doi: 10.1007/s00384-010-1128-x

Kalimutho, Murugan, Blanco, Giovanna Del Vecchio, Gravina, Paolo, Cretella, Micaela, Mannucci, Liliana, Mannisi, Elena, Formosa, Amanda, Pallone, Francesco, Federici, Giorgio and Bernardini, Sergio (2010). Quantitative denaturing high performance liquid chromatography (Q-dHPLC) detection of APC long DNA in faeces from patients with colorectal cancer. Clinical Chemistry and Laboratory Medicine, 48 (9), 1303-1311. doi: 10.1515/CCLM.2010.245

Raninga, P., Lee, A., Sinha, D., Shin, Y-Y., Mittal, D., Kalimutho, M. and Khanna, K. K. (2019). Synergistic anti-cancer activity of auranofin with anti-PD-L1 therapy in triple negative breast cancer. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 1 October 2019. Oxford, United Kingdom: Oxford University Press.

Sinha, D., Kalimutho, M., Bain, A.L. and Khanna, K.K. (2018). CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo. 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherlands, 30 June – 3 July 2018. London, United Kingdom: Elsevier. doi: 10.1136/esmoopen-2018-eacr25.730

Sinha, D., Kalimutho, M., Lopez, A. J. and Khanna, K. K. (2017). Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: OXFORD UNIV.

Raninga, P., Kalimutho, M., Sinha, D., Bain, A., Tonissen, K. and Khanna, K. K. (2017). Targeting thioredoxin reductase 1 in novel combination therapies in p53 mutant triple negative breast cancer. 42nd European Society for Medical Oncology Congress (ESMO), Madrid, Spain, 8-12 September 2017. Oxford, United Kingdom: Oxford University Press.

Sinha, Debottam, Kalimutho, Murugan, Lopez, J. Alejandro and Khanna, Kum Kum (2017). Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC , United States, 1-5 April 2017. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2017-1144

Whitehall, Vicki, Borowsky, Jennifer, Bond, Catherine, Bettington, Mark, Pearson, Sally-Ann, Kalimutho, Murugan, Liu, John, Dumenil, Troy, McKeone, Diane, Jamieson, Saara, Fernando, Winnie, Fennell, Lochlan, Clouston, Andrew, Rosty, Christophe, Brown, Ian, Walker, Neal and Leggett, Barbara (2017). Abstract PR04: Wnt and MAPK pathway activation in conventional and serrated colorectal neoplasia. AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes, Tampa, FL, United States, 17-20 September 2016. Philadelphia, PA, United States: American Association for Cancer Research. doi: 10.1158/1538-7445.crc16-pr04

Bond, C., Kalimutho, M., Bettington, M., Pearson, S., Leggett, B. and Whitehall, V. (2015). Effects of the porcupine inhibitor, LGK974, on RNF43 mutant and wild type colorectal cancer cell lines. Abstracts of Gastro 2015 GESA‐AGW and WGO International Congress, Gastroenterological Society of Australia Australian Gastroenterology Week 2015 | World Congress of Gastroenterology, Brisbane, QLD, Australia, 28 September‐2 October 2015. Richmond, VIC, Australia: John Wiley & Sons.

Dr Murugan Kalimutho

Publications

Journal Articles

Conference Papers